Objective-Although biglycan (BGN) and oxidized low-density lipoprotein (oxLDL) accumulation has been observed in calcific, stenotic aortic valves, their role in the pathogenesis of calcific aortic valve disease is poorly understood. We hypothesized that soluble BGN induces the osteogenic response in human aortic valve interstitial cells via Toll-like receptor (TLR) 2 and TLR4 and mediates the proosteogenic effect of oxLDL. Methods and Results-Aortic valve interstitial cells of stenotic valves express higher levels of BGN. Stimulation of cells from normal valves with BGN increased the expression of bone morphogenetic protein-2 (BMP-2) and alkaline phosphatase (ALP) among the chondrogenic/osteogenic markers examined and caused accumulation of calcium deposits. TLR2 silencing, but not TLR4 silencing, reduced BMP-2 and ALP levels after BGN stimulation although coimmunoprecipitation revealed that BGN interacts with both TLR2 and TLR4. BGN induced the phosphorylation of extracellular signal-regulated protein kinase-1/2, p38 mitogen-activated protein kinase and nuclear factor-κB. Inhibition of extracellular-regulated kinase-1/2 markedly reduced the upregulation of BMP-2 and ALP expression by BGN whereas inhibition of p38 mitogen-activated protein kinase or nuclear factor-κB had a moderate effect. Stimulation of aortic valve interstitial cells with oxLDL upregulated BGN expression and release. Knockdown and neutralization of BGN reduced the effect of oxLDL on BMP-2 and ALP expression. Key Words: biglycan ◼ oxidized low-density lipoprotein ◼ aortic valve interstitial cell ◼ bone morphogenetic protein-2 ◼ Toll-like receptor-2
C alcific aortic valve disease is a chronic inflammatory disease. This disease affects a large number of people ≥65 and is the second most common indication for cardiac surgery. Because of limited understanding of the mechanisms of valvular calcification and stenosis, pharmacological intervention is currently unavailable.
Calcific aortic valve diasease was originally considered to be the result of natural degenerative aging of inert matrixbased tissue. In recent years, the active and cell-based nature of the disease process has been recognized, and thus, the potential for pharmacological intervention has risen. 1, 2 Although the pathogenic mechanism of calcific aortic valve disease remains elusive, the inflammatory and proosteogenic changes in valvular tissue are implicated in the development and progression of this disease. Aortic valve calcification and stenosis occur within the valve tissue, and aortic valve interstitial cells (AVICs) have been demonstrated to play an important role in the inflammatory and osteogenic responses. 3, 4 Our recent studies found that stimulation of Toll-like receptor (TLR) 2 or TLR4 in human AVICs with bacterial ligands not only elicits the production of inflammatory mediators but also induces the expression of bone morphogenetic protein-2 (BMP-2) and alkaline phosphatase (ALP), 2 important biomarkers of calcific aortic valve disease. 5, 6 Further, AVICs isolated from stenotic aortic valves exhibit elevated levels of BMP-2 and ALP in the absence of stimulation. 6, 7 However, the mechanism underlying the proosteogenic phenotype of AVICs of diseased valves is unclear, and the role of endogenous activators of TLR2 and TLR4 in the inflammatory and osteogenic responses in human AVICs remains to be determined.
Biglycan (BGN), a member of the family of small proteoglycans, is a stationary component of the extracellular matrix and is present in most tissues. 8 However, when BGN is secreted by cells or released from the extracellular matrix, it becomes available in a soluble form. Soluble BGN has been found to induce cytokine production in macrophages through TLR2 and TLR4. 9, 10 Interestingly, BGN accumulates in calcific, stenotic areas of human aortic valves, and soluble BGN is capable of inducing AVIC expression of a phospholipid transfer protein through TLR2. 11 It is unknown, however, whether AVICs of diseased valve express higher levels of BGN and whether soluble BGN induces an osteogenic response in human AVICs. Therefore, the present study is sought to examine BGN expression in AVICs from diseased human aortic valves and to determine the effect of BGN on the expression of chondrogenic/osteogenic biomarkers in human AVICs.
Oxidized low-density lipoprotein (oxLDL) is implicated in vascular calcification associated with atherosclerosis. 12, 13 Elevated levels of oxLDL in blood correlate with aortic valve calcification and fibrosis, 14 and oxLDL accumulation in calcific, stenotic aortic valves is well described. 11, [15] [16] [17] [18] [19] Our recent study found that oxLDL is capable of upregulating the expression of BMP-2 in human coronary artery endothelial cells whereas native LDL is not. 20 oxLDL has been shown to modulate BGN expression in vascular smooth muscle cells. 21 However, it remains unknown whether BGN contributes to the mechanism underlying the proosteogenic effect of oxLDL. Further, it is unclear whether oxLDL is proosteogenic to human AVICs. We aimed to determine the effect of oxLDL on the expression of BMP-2 and ALP, as well as the role of BGN in the effect of oxLDL on human AVICs.
We hypothesized that soluble BGN induces an osteogenic response in human AVICs via TLR2 and TLR4 and mediates the proosteogenic effect of oxLDL on human AVICs. The purpose of this study was to determine: (1) whether BGN expression is upregulated in AVICs of stenotic human aortic valves, (2) the effect of soluble BGN on the expression of chondrogenic/osteogenic biomarkers by human AVICs, (3) the mechanism by which soluble BGN exerts its effect, (4) whether oxLDL induces BGN expression and release in AVICs, and (5) the role of BGN in oxLDL effect on AVICs.
Materials and Methods

Materials
Antibodies against BMP-2, TLR2, TLR4, runt-related transcription factor 2 (Runx2), osterix (Osx), Msh homeobox 2 (Msx2), POU domain, class 1, transcription factor 1 (Pit-1), and SRY (sex determining region Y)-box 9 (Sox9), as well as specific small interfering RNA (siRNA) for human TLR2, TLR4, and BGN and scrambled siRNA, were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Antibodies against phosphorylated extracellular-regulated kinase (ERK) 1/2, total ERK1/2, phosphorylated p38 mitogen-activated protein kinase (MAPK), total p38 MAPK, phosphorylated NF-κB, and total NF-κB were purchased from Cell Signaling, Inc (Beverly, MA). Medium 199 was purchased from Lonza (Walkersville, MD). Recombinant human BGN (expressed by a murine myeloma cell line; endotoxin free), antibodies against BGN and ALP, were purchased from R&D System (Minneapolis, MN). BGN ELISA kit was obtained from Uscn Life Science, Inc (Germany). oxLDL was purchased from Biomedical Technologies Inc (Stoughton, MA). HiPerFect transfection reagent and other transfection-related reagents were purchased from Dharmacon (Lafayette, CO). Pierce Cell Lysis Buffer for immunoprecipitation was purchased from Thermo Fisher Scientific (Rockford, IL). All other chemicals and reagents, including Bay11-7082, were from Sigma-Aldrich Chemical Co (St. Louis, MO).
Cell Isolation and Treatment
Stenotic aortic valve leaflets were obtained from 5 patients (4 males and 1 female; age 55.8±13.2 years) undergoing valve replacement at the University of Colorado Hospital. Normal aortic valve leaflets were collected from the explanted hearts of 6 patients (4 males and 2 females; age 59.0±8.1 years) with cardiomyopathy and undergoing heart transplantation at the University of Colorado Hospital. These valve leaflets were thin and did not exhibit histological abnormality. All patients gave informed consent for the use of their valves for this study approved by the University of Colorado Denver Institutional Review Board.
AVICs were isolated and cultured using a previously described method 22 with modification. 5 Briefly, valve leaflets were subjected to sequential digestions with collagenase, and cells were collected by centrifugation. Cells were cultured in M199 growth medium containing penicillin G, streptomycin, amphotericin B, and 10% fetal bovine serum. Cells from passages 4 to 6 were used for this study. Cells were subcultured on plates and treated when they reached 80% to 90% confluence.
To determine the effect of soluble BGN on the expression of BMP-2, ALP, Runx2, Osx, Msx2, Pit-1, and Sox9, cells from normal valves were treated with recombinant BGN (0.05, 0.10, and 0.20 μg/mL) for 48 hours. Levels of these chondrogenic/osteogenic biomarkers in cell lysates were assessed by immunoblotting.
The effect of BGN on phosphorylation of ERK1/2, p38 MAPK, and nuclear factor-κB (NF-κB) was determined after stimulation of cells with BGN for 60 to 240 minutes. To determine the role of ERK1/2, p38 MAPK, and NF-κB in the effect of BGN on human AVICs, ERK1/2 inhibitor (PD98059; 10-40 μmol/L), p38 MAPK inhibitor (SB203580; 5-20 μmol/L), and IBκ kinase inhibitor (Bay11-7082; 5-10 μmol/L) were added to culture medium 30 minutes before the addition of BGN.
To determine the effects of oxLDL on BGN expression and release, cells were stimulated with oxLDL (20 and 40 μg/mL) for 2 to 24 hours. Levels of BGN mRNA and protein in cells and levels of BGN protein in culture medium were analyzed.
To determine the role of BGN in oxLDL-induced osteogenic response, cells were treated with oxLDL for 48 hours in the presence of a polyclonal antibody against human BGN (10 μg/mL) or after pretreatment with human BGN siRNA. Levels of BMP-2 and ALP in cell lysate were assessed.
Immunofluorescent Staining
Immunofluorescent staining was applied to character cell cultures as described previously. 23 After permeabilization with a methanol/acetone mixture, cells on chamber slides were fixed in 4% paraformaldehyde, incubated with a rabbit polyclonal antibody against human α-smooth muscle actin overnight at 4 o C. After washing with PBS, cells were incubated with Cy3-tagged secondary antibody against the primary antibody (imaged on the red channel). Nuclei were stained with bis-benzimide (4′,6-diamidino-2-phenylindole, imaged on the blue channel), and glycoproteins on cell surfaces with Alexa 488-tagged wheat germ agglutinin (imaged on the green channel). Microscopy was performed with a Leica DMRXA digital microscope (Leica Mikroskopie und Systeme GmbH, Wetzlar, Germany) equipped with Slidebook software (I. I. I. Inc, Denver, CO).
Gene Knockdown
To knockdown TLR2, TLR4, and BGN, cells (60%-70% confluent) in 24-well plates were incubated with a mixture of siRNA (60 nmol/L) and transfection reagent (6 μL per mL of medium) for 48 hours. Control cells were treated with scrambled siRNA and transfection reagent.
Real-Time Reverse Transcription Polymerase Chain Reaction Analysis
Total RNA was extracted using a Qiagen RNeasy Mini Kit (Valencia, CA). Reverse transcription and polymerase chain reaction were performed in triplicate using iScriptTM cDNA Synthesis Kit (BioRad, Hercules, CA) and iQ SYBR Green Supermix according to the manufacturer's instructions. Amplification was carried out for 40 cycles including denaturation at 94°C for 10 seconds and annealing/ extension at 59°C for 30 seconds. The following primers were used to amplify specific cDNA fragments: BGN (forward: 5′-TGCAGA ACA ACG ACA TCT CC-3′; reverse:5′-GCC TTC TCA TGG ATC TTG GA-3′) (GenBank accession number NM_001711); GAPDH (forward: 5′-CAT GGC CTC CAA GGA GTA AG-3′; reverse: 5′-AGG GGT CTA CAT GGC AAC TG-3′). BGN mRNA levels were quantified by real-time polymerase chain reaction using the iQ 5 Multicolor Real-time PCR Detection system (Bio-Rad, Hercules, CA). BGN mRNA levels normalized to GAPDH mRNA were calculated using the 2 −ΔΔ T method.
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Immunoblotting
Western blotting was applied to analyze BGN, BMP-2, ALP, Runx2, Osx, Msx2, Pit-1, Sox9, TLR2, TLR4, phosphorylated and total ERK1/2, phosphorylated and total p38 MAPK, and phosphorylated and total NF-κB, with β-actin as a loading control. After stimulation, human AVICs were lysed in a sample buffer (100 mmol/L Tris-HCl; pH 6.8; 2% SDS; 0.02% bromophenol blue; and 10% glycerol). Cell lysates were resolved on 4% to 20% SDS-PAGE gels and the proteins were transferred onto polyvinylidene difluoride membranes. After being blocked with 5% skim milk solution, membranes were incubated with primary antibodies, followed by peroxidase-linked secondary antibodies specific to the primary antibodies. Protein bands were revealed using the enhanced chemiluminescence system. Band density was analyzed using the National Institutes of Health ImageJ software (Wayne Rasband, National Institutes of Health, Bethesda, MD).
ELISA
Cell culture supernatants were collected. BGN levels were analyzed using an ELISA kit following the manufacturer's protocol.
Alizarin Red S Staining
Alizarin red S staining for calcium deposits was performed as described previously. 6 Briefly, cell monolayers were washed twice with PBS and fixed for 15 minutes in 4% paraformaldehyde, followed by incubation with 0.2% alizarin red solution (pH 4.2) for 30 minutes. Excessive dye was removed by washing with distilled water. Alizarin red staining was examined and photographed with a Nikon Eclipse TS100 microscope (Tokyo, Japan). To quantitatively analyze Alizarin red stain, wells were rinsed with distilled water, and alizarin red stains were bleached with 10% acetic acid at 85 o C. Supernatant was spectrophotometrically analyzed at 450 nm. 25 
Coimmunoprecipitation
Human AVICs (80%-90% confluent) in 6-well plates were gently rinsed 3 times with PBS. Cells were lysed in Pierce Cell Lysis Buffer (25 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% tergitol-type NP-40, and 5% glycerol, pH 7.4), and the lysates centrifuged at 112g for 10 minutes at 4°C. Clarified lysates were incubated with a mouse monoclonal antibody against human TLR2 (4 μg/sample), human TLR4 (4 μg/sample), or nonimmune mouse IgG (4 μg/ sample) with G-coupled Sepharose beads overnight at 4°C with rocking. Precipitation was performed at 4°C for 2 hours using 20 μL of protein G-agarose per sample. The beads were gently washed 5 times with 0.5 mL of lysis buffer and resuspended in 100 μL of 2× SDS sample buffer. BGN, TLR2 and TLR4 were analyzed by immunoblotting.
Statistical Analysis
Data are presented as mean±SE. Statistical analysis was performed using StatView software (Abacus Concepts, Calabasas, CA 
Results
AVICs of Stenotic Valves Express High Levels of BGN
We analyzed BGN mRNA and protein levels in AVICs isolated from normal and stenotic valves. As shown in Figure 1A and 1B, cells from diseased valves had markedly higher levels of BGN mRNA (P<0.05) and protein.
To examine whether cultures of AVICs from normal and stenotic aortic valves are phenotypically comparable, we characterized cell cultures. Phase contrast images showed comparable morphology between AVICs from normal valves and AVICs from stenotic valves ( Figure 1C) . However, AVICs of stenotic aortic valves grew slower. When equal numbers of cells were seeded, cultures of cells from stenotic valves had lower density after growth (49653±2675 cells/field using a 20× objective versus 77903±3819 cells/field in normal cell cultures; P<0.05). Immunofluorescent staining with a specific antibody against human α-smooth muscle actin revealed that greater than 80% of cells are positive for α-smooth muscle actin in AVICs from either normal valves or stenotic valves. However, AVICs from stenotic valves exhibited abundant stress fibers ( Figure 1C ).
Soluble BGN Upregulates the Expression of BMP-2 and ALP in Human AVICs
To determine the effect of soluble BGN on the expression of chondrogenic/osteogenic biomarkers by human AVICs, we analyzed the levels of BMP-2, ALP, Runx2, Osx, Msx2, Pit-1, and Sox9 after BGN treatment. As shown in Figure 2A and 2B, stimulation of cells with recombinant human BGN resulted in a dose-dependent increase in protein levels of BMP-2 and ALP and ALP activity. More importantly, prolonged stimulation with BGN promoted the accumulation of calcium deposits and the formation of calcification nodules in human AVIC culture ( Figure 2C ). However, BGN had no effect on the levels of Runx2, Msx2, Pit-1, and Sox9 although it slightly upregulated the levels of Osx (online-only Data Supplement). These results demonstrate that soluble BGN is potent to upregulate the expression of BMP-2 and ALP and that prolonged exposure to soluble BGN induces proosteogenic changes in human AVICs.
Soluble BGN Upregulates BMP-2 and ALP Expression by Human AVICs Primarily Through TLR2
Soluble BGN has been reported to activate TLR2 and TLR4 in macrophages. 9 We have found that stimulation of TLR2 or TLR4 upregulates the expression of BMP-2 and ALP in human AVICs. 6 To determine whether these 2 innate immune receptors play a role in mediating BGN-induced BMP-2 and ALP expression in human AVICs, we applied specific siRNA to knockdown TLR2 and TLR4. As shown in Figure 3A , silencing of TLR2 markedly reduced protein levels of BMP-2 and ALP after BGN stimulation. However, silencing of TLR4 had minimal effects ( Figure 3A) . The results suggest that TLR2, but not TLR4, plays a major role in the upregulation of BMP-2 and ALP expression in human AVICs by soluble BGN.
To examine whether BGN interacts with TLR2 and TLR4, we performed coimmunoprecipitation. Interestingly, both TLR2 and TLR4 were coimmunoprecipitated with BGN in cells exposed to recombinant BGN ( Figure 3B ). However, higher levels of TLR2 were coimmunoprecipitated with BGN, indicating a preferential or stronger interaction of BGN with TLR2.
ERK1/2 Plays a Major Role in the Mechanism
Underlying BGN-Induced BMP-2 and ALP Expression TLR2 activates multiple proinflammatory signaling pathways, including ERK1/2, p38 MAPK, and NF-κB pathways.
26 ERK1/2, p38 MAPK, and NF-κB pathways have previously been shown to play important roles in regulating osteoblast activity. 27, 28 We determined the effect of BGN on phosphorylation of these signaling molecules. We found that BGN induced the phosphorylation of ERK1/2, p38 MAPK, and NF-κB ( Figure 4A ). To determine the role of ERK1/2, p38 MAPK, and NF-κB in BGN-induced expression of BMP-2 and ALP, we applied specific inhibitors before stimulation of cells with BGN. Inhibition of ERK1/2 with PD98059 dose dependently reduced the levels of BMP-2 and ALP after BGN stimulation ( Figure 4B ). Inhibition of p38 MAPK with SB203580 and inhibition of NF-κB with Bay11-7082 also attenuated BMP-2 and ALP expression ( Figure 4C and  4D) . However, the effect of inhibition of p38 MAPK or NF-κB was moderate in comparison with that of ERK1/2 inhibition. Therefore, ERK1/2, p38 MAPK, and NF-κB are all involved in mediating the upregulation of BMP-2 and ALP expression in human AVICs by BGN, and ERK1/2 plays a major role.
TLR2 Mediates ERK1/2 Phosphorylation and Calcium Deposit Formation Induced by BGN
To determine whether TLR2 mediates BGN-induced ERK1/2 phosphorylation, we stimulated cells with BGN (0.10 μg/mL) for 60 to 240 minutes in the presence of a TLR2-neutralizing antibody (10 μg/mL). The results in Figure 5A show that TLR2-neutralizing antibody suppressed ERK1/2 phosphorylation at all time points examined. A maximal reduction in ERK1/2 phosphorylation was observed at 240 minutes after BGN stimulation.
To confirm the role of TLR2 in BGN-induced calcium deposit formation, we stimulated cells cultured in conditioning medium with BGN (0.10 μg/mL) for 21 days in the presence of the TLR2-neutralizing antibody (10 μg/mL). Alizarin Red S staining revealed that TLR2-neutralizing antibody significantly reduced the formation of calcium deposits ( Figure 5B ). Together, these results demonstrate that TLR2 mediates BGN-induced ERK1/2 phosphorylation and is involved in the mechanism underlying calcium deposit formation induced by BGN.
oxLDL Promotes BGN Expression and Release in Human AVICs
We have reported that oxLDL induces the expression of BMP-2 in human coronary artery endothelial cells whereas native LDL does not have an effect. 20 In the present study, we observed that stimulation of human AVICs with oxLDL increased cellular levels of BGN protein ( Figure 6A ). To examine whether the upregulation of BGN protein by oxLDL involves gene transcription, we employed real-time reverse transcription polymerase chain reaction to determine the effect of oxLDL on BGN mRNA levels. As shown in Figure 6B , BGN mRNA levels increased in a time-dependent fashion after oxLDL stimulation. Elevated levels of BGN mRNA were detected at 4 hours of exposure to oxLDL, and the maximal increase (3.19-fold; P<0.05) in BGN mRNA was observed at 8 hours. Thus, oxLDL induces BGN gene expression to increase BGN protein levels in human AVICs.
To determine whether oxLDL induces the secretion of BGN, we analyzed BGN levels in culture supernatants using ELISA. BGN levels in culture supernatants increased over time after oxLDL stimulation ( Figure 6C ). Extracellular BGN levels increased by 4.5-fold (P<0.05) at 24 hours of stimulation with 20 μg/mL of oxLDL. Together, the results demonstrate that oxLDL upregulates BGN expression and promotes BGN release in human AVICs.
BGN Contributes to the Mechanism by Which OxLDL Induces the Expression of BMP-2 and ALP in Human AVICs
To determine whether BGN is involved in the mechanism underlying the upregulation of BMP-2 and ALP expression by oxLDL, we added a polyclonal antibody against human BGN to culture medium before oxLDL stimulation. As shown in Figure 7A , anti-BGN reduced the effect of oxLDL on the expression of BMP-2 and ALP whereas isotype-matching nonimmune IgG had no effect. To further determine the role of BGN in oxLDL-induced BMP-2 and ALP expression, we treated cells with BGN siRNA. Figure 7B shows that silencing of BGN reduced the levels of BMP-2 and ALP proteins after oxLDL stimulation. These results indicate that BGN contributes to the mechanism by which oxLDL induces these osteogenic mediators in human AVICs.
Discussion
In the present study, we found that AVICs of stenotic valves express greater levels of BGN than cells of normal valves. Importantly, soluble BGN is capable of inducing BMP-2 and ALP expression, and this effect of BGN on human AVICs is mediated primarily by TLR2 and involves activation of the ERK1/2, p38 MAPK, and NF-κB pathways. Further, we demonstrate that oxLDL promotes BGN expression and release by human AVICs and that BGN plays a crucial role in oxLDL-induced expression of BMP-2 and ALP in human AVICs. These findings provide novel insights into the molecular mechanisms by which an endogenous agent induces the osteogenic response in human AVICs. These findings highlight the possibility of pharmacological intervention for treatment of calcific aortic valve disease in its early stage.
Soluble BGN Is Potent to Induce the Expression of BMP-2 and ALP in Human AVICs
Macromolecules of the extracellular matrix are commonly thought to function as pure structural components. However, there is growing evidence that the extracellular matrix exerts more complex actions than being a mere scaffold for cells to attach to, including direct regulation of cellular functions. 8, [29] [30] [31] [32] In this regard, several studies in macrophages have found that BGN induces cytokine production. 9 Moreover, BGN modulates BMP signaling and is involved in the regulation of osteoblast differentiation. [33] [34] [35] [36] Several studies have reported BGN accumulation in calcific, stenotic areas of aortic valves. 11 However, the role of soluble BGN in the pathogenesis of calcific aortic stenosis is unclear, and the effect of soluble BGN on valve cells remains to be determined. The results of this study show that soluble BGN induces the expression of osteogenic mediators BMP-2 and ALP in human AVICs. However, BGN at the concentrations tested had no effect on the expression of Runx2, Msx2, Pit-1, and Sox9 and only moderately upregulated the levels of Osx. It appears that BMP-2 and ALP responses in human AVICs are sensitive to soluble BGN. BMP-2 is a potent osteogenic factor and plays an important role in vascular and aortic valve calcification. In this regard, high levels of BMP-2 expression have been found in calcified human atherosclerotic plaque, and smooth muscle cells isolated from the atherogenic aortic wall express BMP-2 in vitro and form calcification nodules with prolonged culture. 37 In addition, recombinant BMP-2 promotes phosphate uptake and calcification in human vascular smooth muscle cells in vitro. 38 More importantly, overexpression of BMP-2 accelerates atherosclerotic intimal calcification in apolipoprotein E knockout mice. 39 In calcific aortic valve disease, BMP-2 accumulation in valve leaflets is evident in the early stage of this desease. 40 We have found that stimulation of human AVICs with recombinant BMP-2 in vitro upregulates ALP expression and induces calcification nodule formation. 6 Because soluble BGN is potent to upregulate BMP-2 expression in human AVICs, it may contribute to the mechanism of aortic valve calcification. The results of the present study show that prolonged exposure to soluble BGN causes AVIC calcification. These findings indicate a pathobiological role of soluble BGN in the cell-based development and progression of calcific aortic valve disease.
It is likely that BMP-2 plays a critical role in mediating the proosteogenic changes induced by soluble BGN as recombinant BMP-2 upregulates ALP expression and induces calcification nodule formation in human AVICs. 6 Runx2 interacts with Smad in osteoblasts, and the Runx2−Smad complex mediates BMP-promoted osteoblast differentiation and bone formation. 41 Osx−nuclear factor of activated T cells c1 complex has also been found to play an important role in the transcriptional program of osteoblasts associated with bone formation. 42 The transcriptional mechanism of the proosteogenic programming of AVICs downstream of the novel BGN−TLR2−BMP2 axis remains unknown from the present study. However, BGN at the concentrations tested show that treatment with specific small interfering RNA (siRNA) reduced cellular TLR2 and TLR4 levels. Representative immunoblots and densitometric data show that silencing TLR2 markedly reduced cellular bone morphogenetic protein-2 (BMP-2) and alkaline phosphatase (ALP) levels after treatment with BGN (0.10 μg/mL for 48 hours) whereas silencing TLR4 had a minor effect on BGN-induced BMP-2 and ALP expression. n=3 in each group; *P<0.05 vs untreated control; #P<0.05 vs BGN alone; †P<0.05 vs BGN+scrambled siRNA. B, A higher level of TLR2 and a lower level of TLR4 are coimmunoprecipitated with BGN in cells incubated with BGN (0.10 μg/mL for 2 hours).
did not affect the expression of Runx2, Msx2, Pit-1, and Sox9 and only moderately upregulated the levels of Osx. It is possible that modulation of macromolecular assembly of the transcriptional complexes and their nuclear redistribution is involved in mediating AVIC proosteogenic programming.
Further studies are needed to elucidate the molecular mechanism downstream of the BGN-TLR2-BMP-2 axis.
The results of this study also show that AVICs isolated from stenotic valves express greater levels of BGN in vitro. As BGN is involved in tissue repair during and after injury, it is likely that valvular damage associated with the disease process results in a phenotypic change in AVICs of stenotic valves that leads to upregulated expression of BGN. The augmented expression of BGN mRNA and protein in vitro in diseased AVICs after >3 passages indicates that the phenotypic change is long-lasting. One of the limitations of this study, however, is that the diseased AVICs studied were from valves with severe stenosis. Although AVICs were isolated from tissues with relatively minor pathological changes, the findings may not reflect the pathobiology of AVICs in the early stage of calcific aortic valve disease. Nevertheless, the results show that AVICs of normal and diseased aortic valves are morphologically comparable and both exhibit a myofibroblastic phenotype. It is likely that the augmented expression of BGN by AVICs of diseased valves is because of an alteration of the cellular signaling mechanisms that regulate BGN expression. 
TLR2 Plays a Major Role in Mediating the Effect of BGN
In the present study, we observed that both TLR2 and TLR4 are coimmunoprecipitated with BGN after treatment of cells with BGN although the level of TLR2 in the coimmunoprecipitants is higher. The results indicate a molecular interaction of BGN with these 2 innate immune receptors. However, the potency of BGN for the induction of BMP-2 and ALP expression in human AVICs is markedly attenuated by knockdown of TLR2, and knockdown of TLR4 has a minimal effect. These results demonstrate that soluble BGN upregulates BMP-2 and ALP expression in human AVICs primarily through the TLR2 pathway and are consistent with a previous study in which the effect of BGN on the expression of a phospholipid transfer protein in AVICs is suppressed by a TLR2-neutralizing antibody. 11 Further evidence that BGN-induced calcium deposit formation is reduced by a TLR2-neutralizing antibody ( Figure  5B ) confirmed the important role of TLR2 in mediating the proosteogenic effect of soluble BGN. TLR2 signaling is linked to multiple proinflammatory pathways. 26, 43 The results of this study show that BGN induces the phosphorylation of ERK1/2, p38 MAPK, and NF-κB in human AVICs. All 3 pathways appear to be involved in mediating the induction of BMP-2 and ALP expression by soluble BGN because a specific inhibitor for each of these pathways attenuates the upregulation of BMP-2 and ALP expression after BGN stimulation. It is noteworthy that inhibition of ERK1/2 with PD98059 results in a greater reduction in BMP-2 and ALP levels, with 65.2% reduction in BMP-2 and 61.2% reduction in ALP in the presence of 20 μmol/L of PD98059. Thus, the ERK1/2 pathway appears to have a major role in mediating the TLR2-dependent proosteogenic effect of soluble BGN. To confirm the link between TLR2 and ERK1/2 in human AVICs, we determine the effect of a TLR2-neutralizing antibody on BGN-stimulated ERK1/2 phosphorylation. As shown in Figure 5A , TLR2-neutralizing antibody suppressed BGN-induced ERK1/2 phosphorylation. Therefore, the TLR2−ERK1/2 pathway occupies a major role in mediating the upregulation of BMP-2 and ALP expression in human AVICs by soluble BGN. ERK1/2 can modulate NF-κB activity. 20 The moderate effect of NF-κB inhibition on BMP-2 and ALP expression indicates the NF-κB−dependent action of ERK1/2, if any, is a partial mechanism underlying the role of ERK1/2 in mediating the osteogenic response in human AVICs. Further studies are necessary to determine the downstream molecular mechanisms.
BGN Plays an Important Role in OxLDL-Induced BMP-2 and ALP Expression in Human AVICs
Some pathological characteristics of calcific aortic valve disease resemble those of atherosclerosis, but there are also several distinctions. Although both diseases involve lipid entrapment within the tissue, atherosclerosis exhibits foam cell accumulation, 44 whereas aortic valve disease progresses with leaflet calcification. 1 Our recent study found that oxLDL, but not native LDL, upregulates BMP-2 expression in human coronary artery endothelial cells. 20 Further, oxLDL was reported to induce vascular smooth muscle cell calcification. 45 To understand the role of oxLDL in human AVIC osteogenic response, we stimulated cells with oxLDL and examined cellular levels of BMP-2 and ALP. We observed in this study that oxLDL upregulates the expression of BMP-2 and ALP. The findings are consistent with those obtained in coronary artery endothelial cells and vascular smooth muscle cells and indicate that oxLDL is proosteogenic to human AVICs and may be involved in the cell-based disease process of calcific aortic stenosis.
OxLDL and BGN interact in vascular disease. In this regard, BGN is shown to retain oxLDL, and oxLDL is found to upregulate BGN expression in vascular smooth muscle cells. 21 Our recent study found that oxLDL upregulates BMP-2 expression in human coronary artery endothelial cells through a mechanism involving TLR2 and TLR4. 20 In the present study, we found oxLDL not only induces the expression of BGN mRNA and protein but also promotes BGN release in human AVICs. Because soluble BGN upregulates the expression of BMP-2 and ALP via TLR2, it is likely that BGN plays a role in mediating the proosteogenic effect of oxLDL in human AVICs. Indeed, we found that either knockdown or neutralization of BGN reduced the effect of oxLDL on the expression of BMP-2 and ALP in human AVICs. Thus, BGN may play a role in mediating the effect of oxLDL on aortic valve calcification.
Conclusion
Human AVICs of stenotic valves express greater levels of BGN. Soluble BGN induces the expression of BMP-2 and ALP in human AVICs primarily through interaction with TLR2 and activation of the ERK1/2 pathway. Moreover, oxLDL promotes BGN expression and release in human AVICs, and BGN mediates the proosteogenic effect of oxLDL on human AVICs. These findings suggest that BGN and oxLDL may contribute to the mechanism underlying the development and progression of calcific aortic valve disease through upregulation of AVIC expression of BMP-2 and ALP.
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